Psychostimulants in the treatment of depression

被引:1
作者
Richieri, Raphaelle [1 ,2 ]
Adida, Marc [1 ]
Boyer, Laurent [2 ]
Lancon, Christophe [1 ,2 ]
机构
[1] CHU St Marguerite, F-13274 Marseille 09, France
[2] Fac Med Marseille, EA 3279, Lab Sante Publ, F-13385 Marseille 05, France
来源
PRESSE MEDICALE | 2013年 / 42卷 / 03期
关键词
PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; METHYLPHENIDATE; FATIGUE; MODAFINIL; AUGMENTATION; GUIDELINES; MANAGEMENT; DISORDERS; SERTRALINE;
D O I
10.1016/j.lpm.2012.04.020
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Psychostimulants promote alertness and reduce fatigues that have suggested their use in the treatment of depressive disorders in the early part of the 20th century. Overall, data support the use of psychostimulants in depression particularly in cases of drug resistance, when there is a severe physical illness or when short-term efficiency is needed, especially in the elderly. Psychostimulants are relatively better tolerated than conventional antidepressants, side effects concern less than 20% of patients. Nevertheless, they have to be prescribed carefully in front of the increased cases of misuse described by the literature and the French national committee of narcotics and psychotropics. Larger randomized, controlled trials with longer follow-up periods are needed to clarify a profile of response to psychostimulants, and assess the risk of developing tolerance or dependence on these substances.
引用
收藏
页码:347 / 352
页数:6
相关论文
共 34 条
[1]   Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2000 British Association for Psychopharmacology guidelines [J].
Anderson, I. M. ;
Ferrier, I. N. ;
Baldwin, R. C. ;
Cowen, P. J. ;
Howard, L. ;
Lewis, G. ;
Matthews, K. ;
McAllister-Williams, R. H. ;
Peveler, R. C. ;
Scott, J. ;
Tylee, A. .
JOURNAL OF PSYCHOPHARMACOLOGY, 2008, 22 (04) :343-396
[2]  
[Anonymous], PRACT GUID TREATM PA
[3]  
[Anonymous], 2004, DEPR MAN DEPR PRIM S
[4]  
ARCAND M, 1993, CAN FAM PHYSICIAN, V39, P2420
[5]   World federation of societies of biological psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders in primary care [J].
Bauer, Michael ;
Bschor, Tom ;
Pfennig, Andrea ;
Whybrow, Peter C. ;
Angst, Jules ;
Versiani, Marcio ;
Moeller, Hans-Juergen .
WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, 2007, 8 (02) :67-104
[6]  
Candy B, 2009, PSYCHOSTIMULANTS DEP
[7]   Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis [J].
Cipriani, Andrea ;
Furukawa, Toshiaki A. ;
Salanti, Georgia ;
Geddes, John R. ;
Higgins, Julian P. T. ;
Churchill, Rachel ;
Watanabe, Norio ;
Nakagawa, Atsuo ;
Omori, Ichiro M. ;
McGuire, Hugh ;
Tansella, Michele ;
Barbui, Corrado .
LANCET, 2009, 373 (9665) :746-758
[8]   The Texas Medication Algorithm Project: Report of the Texas Consensus Conference Panel on medication treatment of major depressive disorder [J].
Crismon, ML ;
Trivedi, M ;
Pigott, TA ;
Rush, AJ ;
Hirschfeld, RMA ;
Kahn, DA ;
DeBattista, C ;
Nelson, JC ;
Nierenberg, AA ;
Sackeim, HA ;
Thase, ME .
JOURNAL OF CLINICAL PSYCHIATRY, 1999, 60 (03) :142-156
[9]   Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: A preliminary double-blind, placebo-controlled study [J].
DeBattista, C ;
Doghramji, K ;
Menza, MA ;
Rosenthal, MH ;
Fieve, RR .
JOURNAL OF CLINICAL PSYCHIATRY, 2003, 64 (09) :1057-1064
[10]   Bupropion - A review of its use in the management of major depressive disorder [J].
Dhillon, Sohita ;
Yang, Lily P. H. ;
Curran, Monique P. .
DRUGS, 2008, 68 (05) :653-689